Intended for healthcare professionals

Editorials

Treatment for impetigo

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7468.695 (Published 23 September 2004) Cite this as: BMJ 2004;329:695
  1. Sander Koning, general practitioner (s.koning@erasmusmc.nl),
  2. Johannes C van der Wouden, researcher
  1. Erasmus MC, University Medical Center Rotterdam, PO Box 1738, Rotterdam 3000 DR, Netherlands
  2. Erasmus MC, University Medical Center Rotterdam, PO Box 1738, Rotterdam 3000 DR, Netherlands

    Evidence favours topical treatment with mupirocin, fusidic acid

    Impetigo is a bacterial skin infection, the fourth most common dermatological skin disorder in children seen in general practice. Most patients are treated by general practitioners. Proper hygiene and adequate treatment supposedly control the infection, but over the past decade the incidence of impetigo has not declined in the Netherlands.1 For the individual patient, impetigo is a minor disease as a cure can be expected within weeks with most treatments. In developed countries, serious complications such as acute glomerulonephritis are rare.2 Nevertheless the impact of an impetigo outbreak can be considerable. The unattractive appearance of the lesions may worry parents, and children are often barred from schools and kindergartens because of fear of spread of the infection. Outbreaks of impetigo caused by multiple resistant staphylococci have been reported.3 4 For the clinician the choice of treatment will be …

    View Full Text

    Log in

    Log in through your institution

    Subscribe

    * For online subscription